JP Morgan upgraded GoodRx from Neutral to Overweight and set a new price target of $10.00 from $7.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2025 | Strong Buy → Outperform | Raymond James | |
| 12/4/2024 | $5.00 | Neutral | Mizuho |
| 8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
| 5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
| 4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
| 3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
144 - GoodRx Holdings, Inc. (0001809519) (Subject)
10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price. "In a healthcare system where affordability too often dictates access, GoodRx remains focused on delivering meaningful savings to patients at scale," said Laura Jensen, Chief Commer
RxSmartSaver powered by GoodRx delivers instant affordability at the pharmacy counter, giving consumers easier access to savings on widely used brand-name medications GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the availability of its brand medication savings solution, RxSmartSaver powered by GoodRx, at Kroger pharmacies nationwide. RxSmartSaver brings medication affordability directly to the pharmacy counter, improving the patient experience while delivering stronger economics for the retail partner. "Friction at the pharmacy counter causes frustration for both pharmacists and consumers, leading millions of people to abandon their pres
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
Raymond James downgraded GoodRx from Strong Buy to Outperform
Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat
Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve
Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T
Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for
Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)